-
1 Comment
Mochida Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 3.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Mochida Pharmaceutical Co., Ltd's total revenue rose by 2.4% to $28B since the same quarter in the previous year.
Its net income has increased by 67.7% to $3B since the same quarter in the previous year.
Based on the above factors, Mochida Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | JP3922800002 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 672M |
|---|---|
| PE Ratio | 17.8 |
| Target Price | None |
| Dividend Yield | 2.8% |
| Beta | -0.03 |
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension. In addition, the company provides Atelec to treat calcium channel blocker with a long-acting hypotensive effect; Tramcet, an analgesic for chronic pain and pain after tooth extraction; Heparin Sodium MOCHIDA, an anticoagulant agent; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Dinagest, a therapeutic agent for endometriosis, adenomyosis, and dysmenorrhea. Further it offers skin care, baby care, personal care, and nursing products. Additionally, the company develops mesalazine, ethyl icosapentate, daridorexant, dotinurad, and treprostinil drugs for the treatment of ulcerative colitis, hypertriglyceridemia, insomnia, gout and hyperuricemia, and pulmonary hypertension associated with interstitial lung disease; and dMD-001, a medical device that is used for the treatment of articular cartilage lesions, as well as dMD-002, which is used for the treatment of cavernous nerve injury. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MFY.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
